Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
•
Scleroderma
•
Eosinophilic Fasciitis
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
When do you consider adding steroid sparing agents?
Related Questions
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
What considerations do you take when using prednisone in patients with systemic sclerosis?
How do you approach symptom control in a patient with diffuse cutaneous systemic sclerosis (dcSSc) and rapidly progressive skin disease?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
How would you counsel a patient with systemic sclerosis who wants to consider microneedling on the face or other skin which is not clearly involved with scleroderma?
When do you consider Mesna for patients taking oral cyclophosphamide?
Would you consider altering immunosuppression in a patient with systemic sclerosis (already on systemic immunosuppression for interstitial lung disease) who has more recently been noted to have LV diastolic dysfunction with some reduction in EF in the absence of other worsening symptoms?
How do you manage trigeminal sensory neuropathy in a patient with systemic sclerosis?
